Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$3.86 +2.4%	$3.56	$2.28 ▼ $6.96	$31.91M	0.55	70,875 shs	16,756 shs
GALT Galectin Therapeutics	$2.80 -1.8%	$1.82	$0.73 ▼ $3.90	$177.47M	0.7	417,600 shs	105,038 shs
RAPT Rapt Therapeutics	$10.48 -0.4%	$8.06	$5.67 ▼ $30.08	$173.75M	-0.09	167,671 shs	61,594 shs
SKYE Skye Bioscience	$3.71 +0.4%	$2.92	$1.14 ▼ $7.47	$115.07M	1.95	509,008 shs	122,346 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	+1.89%	-1.57%	-14.71%	+25.67%	-23.06%
GALT Galectin Therapeutics	+1.79%	+26.67%	+91.28%	+106.52%	+13.10%
RAPT Rapt Therapeutics	-0.85%	+24.64%	+27.67%	+66.35%	-64.93%
SKYE Skye Bioscience	-1.34%	-12.56%	+72.83%	+157.14%	-44.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLNN Clene	3.4581 of 5 stars	3.6	5.0	0.0	2.2	2.5	0.6
GALT Galectin Therapeutics	2.2682 of 5 stars	3.5	2.0	0.0	3.3	1.7	0.0
RAPT Rapt Therapeutics	4.374 of 5 stars	3.1	4.0	4.2	2.5	1.7	1.3
SKYE Skye Bioscience	2.1435 of 5 stars	3.5	4.0	0.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	3.17	Buy	$40.00	936.27% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	114.29% Upside
RAPT Rapt Therapeutics	2.17	Hold	$19.80	89.00% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	348.04% Upside

Current Analyst Ratings Breakdown

Latest CLNN, GALT, SKYE, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$350K	91.17	N/A	N/A	($1.06) per share	-3.64
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
RAPT Rapt Therapeutics	$1.53M	113.25	N/A	N/A	$11.51 per share	0.91
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	N/A	-105.11%	8/6/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/12/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A

Latest CLNN, GALT, SKYE, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	CLNN Clene	-$0.49	N/A	N/A	N/A	$0.06 million	N/A
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	1.36	1.36
GALT Galectin Therapeutics	N/A	0.08	0.08
RAPT Rapt Therapeutics	N/A	21.11	21.11
SKYE Skye Bioscience	N/A	11.85	11.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
GALT Galectin Therapeutics	11.68%
RAPT Rapt Therapeutics	99.09%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
CLNN Clene	35.30%
GALT Galectin Therapeutics	50.10%
RAPT Rapt Therapeutics	2.36%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	8.27 million	5.35 million	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.58 million	Optionable

CLNN, GALT, SKYE, and RAPT Headlines

Recent News About These Companies

SKYE Stock Price Quote | Morningstar

July 11, 2025 | morningstar.comM

Skye Bioscience, Inc. (SKYE) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Skye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a Data

July 6, 2025 | msn.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Rating of "Buy" by Brokerages

July 3, 2025 | marketbeat.com

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

June 25, 2025 | finance.yahoo.com

Skye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...

June 24, 2025 | manilatimes.netM

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - Morningstar

June 24, 2025 | morningstar.comM

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - Nasdaq

June 24, 2025 | nasdaq.com

Skye Bioscience (NASDAQ:SKYE) Receives "Market Outperform" Rating from JMP Securities

June 24, 2025 | marketbeat.com

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment

June 23, 2025 | quiverquant.comQ

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

June 23, 2025 | globenewswire.com

Skye Bioscience (NASDAQ:SKYE) Trading 23.1% Higher - Should You Buy?

June 20, 2025 | marketbeat.com

Skye confirms phase 2 data on nimacimab for obesity expected later this year

June 19, 2025 | msn.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

June 17, 2025 | finance.yahoo.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

June 17, 2025 | globenewswire.com

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

May 23, 2025 | zacks.com

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025 | globenewswire.com

Skye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity Treatment

May 21, 2025 | nasdaq.com

Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’

May 20, 2025 | healio.comH

Arecor shares climb 18% on collaboration with Skye Bioscience

May 19, 2025 | lse.co.uk

Arecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate Nimacimab

May 19, 2025 | cambridgenetwork.co.ukC

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, GALT, SKYE, and RAPT Company Descriptions

Clene NASDAQ:CLNN

$3.86 +0.09 (+2.39%)

As of 12:32 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Galectin Therapeutics NASDAQ:GALT

$2.80 -0.05 (-1.75%)

As of 12:34 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Rapt Therapeutics NASDAQ:RAPT

$10.48 -0.04 (-0.42%)

As of 12:36 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Skye Bioscience NASDAQ:SKYE

$3.70 +0.02 (+0.41%)

As of 12:35 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time